Separate terms with OR to return results that match either term.
 
Clear All

9,715 Matching ResultsExport these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) (Ascending) NDC-9 (Product) Generic Name Brand Name Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
63304-0096-30 63304-0096 Erlotinib Erlotinib 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-11 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0135-30 63304-0135 Erlotinib Erlotinib 150.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor EGFR Oral Nov. 5, 2019 In Use
63304-0158-01 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0158-30 63304-0158 Bromocriptine Mesylate Bromocriptine Mesylate 5.0 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Dec. 22, 2016 In Use
63304-0346-05 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-11 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-30 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0346-69 63304-0346 Ondansetron Ondansetron 4.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use
63304-0347-05 63304-0347 Ondansetron Ondansetron 8.0 mg/1 Ancillary Therapy Antiemetic 5HT3 Receptor Antagonist Oral Jan. 10, 2012 In Use

Found 9,715 results in 21 millisecondsExport these results